Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Friday. The firm presently has a $1.25 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price would indicate a potential upside of 19.05% from the stock’s current price.

According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. “

A number of other research analysts have also recently commented on the stock. ValuEngine cut shares of Bellerophon Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 10th. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Bellerophon Therapeutics in a research report on Wednesday, September 6th.

Shares of Bellerophon Therapeutics (BLPH) traded up 1.94% during midday trading on Friday, hitting $1.05. 508,102 shares of the company’s stock were exchanged. Bellerophon Therapeutics has a 1-year low of $0.43 and a 1-year high of $1.69. The stock’s 50 day moving average is $1.09 and its 200-day moving average is $1.23. The stock’s market cap is $37.29 million.

Bellerophon Therapeutics (NASDAQ:BLPH) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03. Analysts predict that Bellerophon Therapeutics will post ($1.12) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Zacks Investment Research Upgrades Bellerophon Therapeutics, Inc. (BLPH) to Buy” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at

Hedge funds and other institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. acquired a new position in shares of Bellerophon Therapeutics during the first quarter worth $125,000. Renaissance Technologies LLC raised its holdings in Bellerophon Therapeutics by 99.7% in the first quarter. Renaissance Technologies LLC now owns 477,400 shares of the biotechnology company’s stock valued at $711,000 after acquiring an additional 238,300 shares in the last quarter. Vanguard Group Inc. raised its holdings in Bellerophon Therapeutics by 52.6% in the second quarter. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company’s stock valued at $821,000 after acquiring an additional 211,111 shares in the last quarter. Finally, Susquehanna International Group LLP acquired a new stake in Bellerophon Therapeutics in the second quarter valued at $1,316,000. 45.85% of the stock is currently owned by institutional investors and hedge funds.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.

Get a free copy of the Zacks research report on Bellerophon Therapeutics (BLPH)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with's FREE daily email newsletter.